Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ocrevus subcutaneous injection

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

Roche Basel Switzerland

Roche drug hits the mark in spinal muscular atrophy studies

Data suggests Risdiplam could improve motor function

- PMLiVE

Roche’s Tecentriq misses survival mark in frontline NSCLC

Keytruda proving hard to beat

- PMLiVE

Labour party divided on Brexit ‘People’s Vote’

Growing support for second referendum being resisted by party leaders

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

- PMLiVE

Roche Diagnostics’ chief heads for the exit

No surprise if Diggelmann resurfaces at diagnostics start-up or rival

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links